Browse Category

Stock Market News 1 December 2025

Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences Corporation (NASDAQ: EXAS) has turned into one of the most closely watched healthcare stocks heading into December 2025, thanks to a blockbuster takeover agreement with Abbott Laboratories, strong Q3 results, and a rapid share‑price rally that has pushed
Danaher (DHR) Stock on December 1, 2025: Q3 Beat, Legal Probes and Fresh Price Targets – Is the Premium Still Worth Paying?

Danaher (DHR) Stock on December 1, 2025: Q3 Beat, Legal Probes and Fresh Price Targets – Is the Premium Still Worth Paying?

Danaher Corporation (NYSE: DHR) enters December 2025 trading around the mid‑$220s per share, a high‑quality life‑sciences and diagnostics name that continues to command a premium valuation — and attract both bullish analysts and governance‑focused law firms. TS2+1 Below is a
1 644 645 646 647 648 739
Go toTop